Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial
Authors' conclusion
TDM reduced prescription of IFX, ETN, and ADA and identified patients benefiting from accelerated drug switch, thereby minimizing treatment failure, risk of toxicity, and unnecessary adverse events.
Study context
- Population
- Adults treated with infliximab (IFX), etanercept (ETN) or ADA for RA, PsA or SpA, independent of disease activityETN or ADA for RA 99 · PsA 48 · or SpA 92
- Participants
- 239 adults
- Comparison
- Standard care plus therapeutic drug monitoring (TDM) vs standard care alone
- Primary endpoint
- Reduced drug prescription
- Follow-up
- 48 weeks
Methodological detailsprospective, open-label
- Prospective
- Open-label
Primary result
As reported in the abstract
Each group vs standard careEstimate (95% CI)P value
TDM
Change in prescribed IFX −12%(−20 to −3)
P = 0.001TDM
Change in prescribed ETN −15%(−29 to 1)
P = 0.01Further findings
| Outcome | Difference (%) (95% CI) | P value |
|---|---|---|
| Interdosing interval, ETN · 48 weeks | +235 (38–432) | P = 0.02 |
| Interdosing interval, ADA · 48 weeks | +28 (6–51) | P = 0.04 |
Time to drug switch
- Time to drug switch was accelerated
- χ2 = 6.03, p = 0.01
Disease activity and self-reported outcomes
- No group differences in disease activity or self-reported outcomes, indicating equally sustained remission
Safety
- No group differences in adverse events
Original publication
Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial. Scand J Rheumatol. Published 31 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →